Staff Profile: Karlie R. Sharma

Karlie R. Sharma, Ph.D.

Program Officer

Office of the Director
Drug Development Partnership Programs

National Center for Advancing Translational Sciences

National Institutes of Health

Email Karlie R. Sharma

Biography

Karlie Sharma joined NCATS in January 2017 as a program officer and NCATS lead for the NIH Common Fund-sponsored Illuminating the Druggable Genome (IDG) program. In this capacity, she oversees the Resource Dissemination and Outreach Center, which is responsible for facilitating widespread access to IDG consortium-generated data and resources and for the overall administration of the IDG Consortium and its relationships with external partners. Sharma also manages multiple teams working to illuminate understudied proteins through the IDG’s R03 pilot project initiative. She is involved in several additional initiatives at NCATS, including the Discovering New Therapeutic Uses for Existing Molecules program and the Small Business Technology Transfer and Small Business Innovation Research program. In addition, Sharma serves as the co-lead on various machine intelligence-related activities.

Sharma received her doctorate in molecular physiology and biophysics from Baylor College of Medicine in Houston. Prior to joining NCATS, Sharma was a postdoctoral fellow in the Laboratory of Host Defenses headed by Dr. Harry Malech at the National Institute of Allergy and Infectious Diseases.

Research Topics

Sharma’s research topics focus on autoimmune diseases, specifically graft-versus-host disease, and developing therapies to treat or prevent occurrence of these diseases. She also has expertise in trinucleotide repeat disorders, such as myotonic dystrophy.

Selected Publications

  1. Recombinant Pregnancy-Specific Glycoprotein 1 Has a Protective Role in a Murine Model of Acute Graft-versus-Host Disease
  2. A Novel Method for Screening Adenosine Receptor Specific Agonists for Use in Adenosine Drug Development
  3. PSG9 Stimulates Increase in FoxP3+ Regulatory T-Cells through the TGF-β1 Pathway
  4. Reduction of toxic RNAs in myotonic dystrophies type 1 and type 2 by the RNA helicase p68/DDX5
  5. GSK3β mediates muscle pathology in myotonic dystrophy